Literature DB >> 15893675

Epidemiology and etiology of multiple sclerosis.

John F Kurtzke1.   

Abstract

The author believes that the Faroese saga provides major insight into what seems to him to be the essential nature of MS: There is a specific, widespread, but unidentified, infection that we call the primary multiple sclerosis affection (PMSA). PMSA is a persistent infection that is transmitted from person to person. A small proportion of persons who has PMSA will develop clinical neurologic multiple sclerosis (CNMS) years later. Prolonged exposure is needed to acquire PMSA. Acquisition follows first adequate exposure. Susceptibility to PMSA is limited to approximately age 11 to age 45 at start of exposure. CNMS is not transmissible.PMSA transmissibility is limited to a period that is less than the usual age of onset of CNMS. On the Faroe Islands, this period is approximately from age 13 to age 26. The existence of PMSA now must be inferred from the presence of CNMS.

Entities:  

Mesh:

Year:  2005        PMID: 15893675     DOI: 10.1016/j.pmr.2005.01.013

Source DB:  PubMed          Journal:  Phys Med Rehabil Clin N Am        ISSN: 1047-9651            Impact factor:   1.784


  19 in total

1.  Migration and multiple sclerosis in United Kingdom and Ireland immigrants to Australia: a reassessment. II. Characteristics of early (pre-1947) compared to later migrants.

Authors:  J G McLeod; S R Hammond; J F Kurtzke
Journal:  J Neurol       Date:  2011-09-23       Impact factor: 4.849

Review 2.  Epstein-barr virus: environmental trigger of multiple sclerosis?

Authors:  Jan D Lünemann; Thomas Kamradt; Roland Martin; Christian Münz
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

3.  Migration and multiple sclerosis in Alaskan military veterans.

Authors:  Mitchell T Wallin; William F Page; John F Kurtzke
Journal:  J Neurol       Date:  2009-04-18       Impact factor: 4.849

4.  Multiple sclerosis in the Republic of San Marino, Italian peninsula: an incidence and prevalence study from a high-risk area.

Authors:  Marta Caniglia-Tenaglia; Susanna Guttmann; Chiara Monaldini; Dario Manzaroli; Mirco Volpini; Maurizio Stumpo; Elisabetta Groppo; Ilaria Casetta; Vittorio Govoni; Mattia Fonderico; Maura Pugliatti; Enrico Granieri
Journal:  Neurol Sci       Date:  2018-04-18       Impact factor: 3.307

Review 5.  Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).

Authors:  Tina KhorshidAhmad; Crystal Acosta; Claudia Cortes; Ted M Lakowski; Surendiran Gangadaran; Michael Namaka
Journal:  Mol Neurobiol       Date:  2015-01-13       Impact factor: 5.590

6.  Variables associated with communicative participation in people with multiple sclerosis: a regression analysis.

Authors:  Carolyn Baylor; Kathryn Yorkston; Alyssa Bamer; Deanna Britton; Dagmar Amtmann
Journal:  Am J Speech Lang Pathol       Date:  2009-11-30       Impact factor: 2.408

Review 7.  Epstein-Barr virus and multiple sclerosis.

Authors:  Jan D Lünemann; Christian Münz
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

8.  Multiple sclerosis in the province of Ferrara : evidence for an increasing trend.

Authors:  E Granieri; N-T Economou; R De Gennaro; M R Tola; L Caniatti; V Govoni; E Fainardi; I Casetta
Journal:  J Neurol       Date:  2007-11-16       Impact factor: 4.849

9.  HLA class I & II alleles in multiple sclerosis patients from Puerto Rico.

Authors:  María T Miranda; Erick Suárez; Muneer Abbas; Angel Chinea; Rafael Tosado; Ida A Mejías; Nawal Boukli; Georgia M Dunston
Journal:  Bol Asoc Med P R       Date:  2013

10.  Spinal fluid IgG antibodies from patients with demyelinating diseases bind multiple sclerosis-associated bacteria.

Authors:  Emily Eckman; Jon D Laman; Kael F Fischer; Bert Lopansri; Tom B Martins; Harry R Hill; John D Kriesel
Journal:  J Mol Med (Berl)       Date:  2021-06-08       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.